As the COVID-19 pandemic continues around the world, global efforts among industry stakeholders to develop, manufacture and secure the supply of proven vaccines have soldiered on.
But there are challenges that procurement bodies face as COVID-19 vaccines are approved on an emergency or conditional basis. In European Pharmaceutical Review, we delve into why traditional vaccine procurement schemes are not fit for purpose during the pandemic and how both governments and manufacturers must adapt to manage the greater level of risk associated with pandemic vaccine development and distribution.
